Carbapenem-Nonsusceptible Acinetobacter baumannii, 8 US Metropolitan Areas, 2012-2015

• Published in: Emerging infectious diseases Vol. 24; no. 4; pp. 727 - 734
• Main Authors: Bulens, Sandra N, Yi, Sarah H, Walters, Maroya S, Jacob, Jesse T, Bower, Chris, Reno, Jessica, Wilson, Lucy, Vaeth, Elisabeth, Bamberg, Wendy, Janelle, Sarah J, Lynfield, Ruth, Vagnone, Paula Snippes, Shaw, Kristin, Kainer, Marion, Muleta, Daniel, Mounsey, Jacqueline, Dumyati, Ghinwa, Concannon, Cathleen, Beldavs, Zintars, Cassidy, P Maureen, Phipps, Erin C, Kenslow, Nicole, Hancock, Emily B, Kallen, Alexander J
• Format: Journal Article
• Language: English
• Published: United States U.S. National Center for Infectious Diseases 01-04-2018; Centers for Disease Control and Prevention
• Subjects: 8 US Metropolitan Areas, 2012–2015; Acinetobacter baumannii - drug effects; Acinetobacter Infections - epidemiology; Acinetobacter Infections - history; Acinetobacter Infections - microbiology; Adolescent; Adult; Aged; Aged, 80 and over; Antibacterial agents; antimicrobial resistance; bacteria; Carbapenem-Nonsusceptible; carbapenems; Carbapenems - pharmacology; Child; Child, Preschool; Drug Resistance, Bacterial; Female; History, 21st Century; Humans; Incidence; Infant; Infant, Newborn; Male; Metropolitan areas; Microbial drug resistance; Middle Aged; Population Surveillance; prevention; surveillance; United States - epidemiology; Young Adult; United States; Acinetobacter baumannii; bacteria; United States; antimicrobial resistance; Emerging Infections Program; carbapenem-nonsusceptible; carbapenems; surveillance; Acinetobacter infections; prevention
• ISSN: 1080-6040; 1080-6059
• DOI: 10.3201/eid2404.171461

In healthcare settings, Acinetobacter spp. bacteria commonly demonstrate antimicrobial resistance, making them a major treatment challenge. Nearly half of Acinetobacter organisms from clinical cultures in the United States are nonsusceptible to carbapenem antimicrobial drugs. During 2012-2015, we conducted laboratory- and population-based surveillance in selected metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee to determine the incidence of carbapenem-nonsusceptible A. baumannii cultured from urine or normally sterile sites and to describe the demographic and clinical characteristics of patients and cases. We identified 621 cases in 537 patients; crude annual incidence was 1.2 cases/100,000 persons. Among 598 cases for which complete data were available, 528 (88.3%) occurred among patients with exposure to a healthcare facility during the preceding year; 506 (84.6%) patients had an indwelling device. Although incidence was lower than for other healthcare-associated pathogens, cases were associated with substantial illness and death.